The global cardiac safety services market size is anticipated to reach USD 1,924 million by 2030 and is projected to grow at a CAGR of 12.0% from 2024 to 20230, according to a report by Grand View Research, Inc. This growth is driven by the alarming prevalence of cardiovascular diseases (CVDs) and significant advancements in medical technology. As per the CDC, in U.S., one person dies due to any cardiovascular disease every 33 seconds, underscoring the critical need for effective cardiac monitoring and intervention. In 2022, heart disease caused 702,880 deaths, representing one in every five deaths and highlighting the vast market potential for cardiac safety services.
Moreover, approximately 805,000 people in the U.S. experience a heart attack each year, with 605,000 being first-time incidents and 200,000 involving individuals who have previously suffered a heart attack. Expanding clinical trials, particularly those focused on cardiovascular diseases or involving therapies with potential cardiovascular impacts, drives the demand for cardiac safety services. As pharmaceutical and biopharmaceutical companies invest in developing new cardiovascular drugs and devices, there is an increased need for specialized cardiac safety assessments to ensure that these products do not adversely affect heart health. This growth in clinical trials, combined with the complexity of modern trials, necessitates robust and reliable cardiac safety services to support drug development and regulatory compliance.
Pharmaceutical companies, medical device manufacturers, and academic institutions continually invest in R&D to drive innovation and growth in the cardiac safety services market. Research initiatives often require sophisticated cardiac safety monitoring to support the development of new therapies and technologies. This investment fosters the development of new cardiac safety solutions and supports continuously improving existing services.
Request a free sample copy or view report summary: Cardiac Safety Services Market Report
Based on service, the ECG/Holter monitors segment led the market with the largest revenue share of 41.0% in 2023. Electrocardiogram (ECG) and Holter monitors are crucial tools for continuous cardiac monitoring, enabling real-time detection of arrhythmias, ischemic episodes, and other cardiovascular conditions
Based on type, the integrated segment led the market with the largest revenue share of 63.17% in 2023. This prominence is primarily driven by the increasing demand for comprehensive, multi-functional cardiac monitoring solutions that offer enhanced accuracy, efficiency, and patient convenience
Based on end use, the pharma & biopharma segment led the market with the largest revenue share of 44.2% in 2023
Grand View Research has segmented the global cardiac safety services market report based on service, type, end-use and region:
Cardiac Safety Service Outlook (Revenue, USD Million, 2018 - 2030)
ECG/Holter Monitors
ECG Patch
Holter Monitors
Blood Pressure Monitors
Aneroid Blood Pressure Monitors
Digital Blood Pressure Monitors
Ambulatory Blood Pressure Monitors
Cardiovascular Imaging
CT
MRI
Ultrasound
Nuclear Medicine
Others
Cardiac Safety Services Type Outlook (Revenue, USD Million, 2018 - 2030)
Integrated
Standalone
Cardiac Safety Services End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharma & Biopharma Companies
CROs
Others
Cardiac Safety Services Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Cardiac Safety Services Market
Medpace
IQVIA
PPD Inc.,
Charles River Laboratories
Wuxi AppTec
Eurofins Scientific
Celerion
Nova Research Laboratories
Laboratory Corporation of America Holdings
Koninklije Philips N.V.
ICON Plc.
SGS S.A.
Clario
Certara
Richmond Pharmacology
Biotrial
"The quality of research they have done for us has been excellent..."